|
1
|
Roe OD and Stella GM: Malignant pleural
mesothelioma: History, controversy and future of a manmade
epidemic. Eur Respir Rev. 24:115–131. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carbone M and Yang H: Mesothelioma: Recent
highlights. Ann Transl Med. 5:2382017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abbott DM, Bortolotto C, Benvenuti S,
Lancia A, Filippi AR and Stella GM: Malignant pleural mesothelioma:
Genetic and microenviromental heterogeneity as an unexpected
reading frame and therapeutic challenge. Cancers (Basel).
12:11862020. View Article : Google Scholar
|
|
4
|
Takagi A, Hirose A, Futakuchi M, Tsuda H
and Kanno J: Dose-dependent mesothelioma induction by
intraperitoneal administration of multi-wall carbon nanotubes in
p53 heterozygous mice. Cancer Sci. 103:1440–1444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takagi A, Hirose A, Nishimura T, Fukumori
N, Ogata A, Ohashi N, Kitajima S and Kanno J: Induction of
mesothelioma in p53+/− mouse by intraperitoneal
application of multi-wall carbon nanotube. J Toxicol Sci.
33:105–116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goodman JE, Nascarella MA and Valberg PA:
Ionizing radiation: A risk factor for mesothelioma. Cancer Causes
Control. 20:1237–1254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pershouse MA, Heivly S and Girtsman T: The
role of SV40 in malignant mesothelioma and other human
malignancies. Inhal Toxicol. 18:995–1000. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bruno C, Tumino R, Fazzo L, Cascone G,
Cernigliaro A, De Santis M, Giurdanella MC, Nicita C, Rollo PC,
Scondotto S, et al: Incidence of pleural mesothelioma in a
community exposed to fibres with fluoro-edenitic composition in
Biancavilla (Sicily, Italy). Ann Ist Super Sanita. 50:111–118.
2014.PubMed/NCBI
|
|
9
|
Carbone M, Ly BH, Dodson RF, Pagano I,
Morris PT, Dogan UA, Gazdar AF, Pass HI and Yang H: Malignant
mesothelioma: Facts, myths, and hypotheses. J Cell Physiol.
227:44–58. 2012. View Article : Google Scholar
|
|
10
|
Xu LL, Yang Y, Wang Z, Wang XJ, Tong ZH
and Shi HZ: Malignant pleural mesothelioma: Diagnostic value of
medical thoracoscopy and long-term prognostic analysis. BMC Pulm
Med. 18:562018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang W, Wu X, Wu L, Zhang W and Zhao X:
Advances in the diagnosis, treatment and prognosis of malignant
pleural mesothelioma. Ann Transl Med. 3:1822015.PubMed/NCBI
|
|
12
|
Bibby AC, Tsim S, Kanellakis N, Ball H,
Talbot DC, Blyth KG, Maskell NA and Psallidas I: Malignant pleural
mesothelioma: An update on investigation, diagnosis and treatment.
Eur Respir Rev. 25:472–486. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cao S, Jin S, Cao J, Shen J, Hu J, Che D,
Pan B, Zhang J, He X, Ding D, et al: Advances in malignant
peritoneal mesothelioma. Int J Colorectal Dis. 30:1–10. 2015.
View Article : Google Scholar
|
|
14
|
Slaby O, Laga R and Sedlacek O:
Therapeutic targeting of non-coding RNAs in cancer. Biochem J.
474:4219–4251. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lo Russo G, Tessari A, Capece M, Galli G,
de Braud F, Garassino MC and Palmieri D: MicroRNAs for the
diagnosis and management of malignant pleural mesothelioma: A
literature review. Front Oncol. 8:6502018. View Article : Google Scholar
|
|
16
|
Tomasetti M, Gaetani S, Monaco F, Neuzil J
and Santarelli L: Epigenetic Regulation of miRNA expression in
malignant mesothelioma: MiRNAs as biomarkers of early diagnosis and
therapy. Front Oncol. 9:12932019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Birnie KA, Prele CM, Thompson PJ, Badrian
B and Mutsaers SE: Targeting microRNA to improve diagnostic and
therapeutic approaches for malignant mesothelioma. Oncotarget.
8:78193–78207. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
ElKhouly AM, Youness RA and Gad MZ:
MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic
mediators in oncological and non-oncological conditions. Noncoding
RNA Res. 5:11–21. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang XP, Hou J, Shen XY, Huang CY, Zhang
XH, Xie YA and Luo XL: MicroRNA-486-5p which is downregulated in
hepatocellular carcinoma, suppresses tumor growth by targeting
PIK3R1. FEBS J. 282:579–594. 2015. View Article : Google Scholar
|
|
21
|
Sun H, Cui C, Xiao F, Wang H, Xu J, Shi X,
Yang Y, Zhang Q, Zheng X, Yang X, et al: MiR-486 regulates
metastasis and chemosensitivity in hepatocellular carcinoma by
targeting CLDN10 and CITRON. Hepatol Res. 45:1312–1322. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu J, Zeng Y, Xu C, Qin H, Lei Z, Shen D,
Liu Z and Huang JA: Expression profile analysis of microRNAs and
downregulated miR-486-5p and miR-30a-5p in non-small cell lung
cancer. Oncol Rep. 34:1779–1786. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Tian X, Han R, Zhang X, Wang X,
Shen H, Xue L, Liu Y, Yan X, Shen J, et al: Downregulation of
miR-486-5p contributes to tumor progression and metastasis by
targeting protumorigenic ARHGAP5 in lung cancer. Oncogene.
33:1181–1189. 2014. View Article : Google Scholar :
|
|
24
|
Rask L, Balslev E, Sokilde R, Hogdall E,
Flyger H, Eriksen J and Litman T: Differential expression of
miR-139, miR-486 and miR-21 in breast cancer patients
sub-classified according to lymph node status. Cell Oncol (Dordr).
37:215–227. 2014. View Article : Google Scholar
|
|
25
|
Yi Y, Lu X, Chen J, Jiao C, Zhong J, Song
Z, Yu X and Lin B: Downregulated miR-486-5p acts as a tumor
suppressor in esophageal squamous cell carcinoma. Exp Ther Med.
12:3411–3416. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang W, Liu B, Sun S, Lan L, Chen Y, Han
S, Li L and Li Z: Downregulation of miR-486-5p enhances the
anti-tumor effect of 5-fluorouracil on pancreatic cancer cells.
Onco Targets Ther. 13:1649–1659. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang M, Li X, Quan X, Yang X, Zhaeng C,
Hao X, Qu R and Zhou B: MiR-486 as an effective biomarker in cancer
diagnosis and prognosis: A systematic review and meta-analysis.
Oncotarget. 9:13948–13958. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mozzoni P, Ampollini L, Goldoni M, Alinovi
R, Tiseo M, Gnetti L, Carbognani P, Rusca M, Mutti A, Percesepe A
and Corradi M: MicroRNA expression in malignant pleural
mesothelioma and asbestosis: A pilot study. Dis Markers.
2017:96459402017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xiang X, Yuan D, Liu Y, Li J, Wen Q, Kong
PY, Gao L, Zhang C, Peng X and Zhang X: PIM1 overexpression in
T-cell lymphomas protects tumor cells from apoptosis and confers
doxorubicin resistance by upregulating c-myc expression. Acta
Biochim Biophys Sin (Shanghai). 50:800–806. 2018. View Article : Google Scholar
|
|
30
|
Cao L, Wang F, Li S, Wang X, Huang D and
Jiang R: PIM1 kinase promotes cell proliferation, metastasis and
tumor growth of lung adenocarcinoma by potentiating the c-MET
signaling pathway. Cancer Lett. 444:116–126. 2019. View Article : Google Scholar
|
|
31
|
Chauhan SS, Toth RK, Jensen CC, Casillas
AL, Kashatus DF and Warfel NA: PIM kinases alter mitochondrial
dynamics and chemosensitivity in lung cancer. Oncogene.
39:2597–2611. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Magnuson NS, Wang Z, Ding G and Reeves R:
Why target PIM1 for cancer diagnosis and treatment? Future Oncol.
6:1461–1478. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mawas AS, Amatya VJ, Suzuki R, Kushitani
K, Mohi El-Din MM and Takeshima Y: PIM1 knockdown inhibits cell
proliferation and invasion of mesothelioma cells. Int J Oncol.
50:1029–1034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang G, Liu Z, Cui G, Wang X and Yang Z:
MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in
breast cancer cells. Tumour Biol. 35:11137–11145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pang W, Tian X, Bai F, Han R, Wang J, Shen
H, Zhang X, Liu Y, Yan X, Jiang F and Xing L: Pim-1 kinase is a
target of miR-486-5p and eukaryotic translation initiation factor
4E, and plays a critical role in lung cancer. Mol Cancer.
13:2402014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jin X, Pang W, Zhang Q and Huang H:
MicroRNA-486-5p improves nonsmall-cell lung cancer chemotherapy
sensitivity and inhibits epithelial-mesenchymal transition by
targeting twinfilin actin binding protein 1. J Int Med Res.
47:3745–3756. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Blower PE, Chung JH, Verducci JS, Lin S,
Park JK, Dai Z, Liu CG, Schmittgen TD, Reinhold WC, Croce CM, et
al: MicroRNAs modulate the chemosensitivity of tumor cells. Mol
Cancer Ther. 7:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Salimian J, Baradaran B, Azimzadeh
Jamalkandi S, Moridikia A and Ahmadi A: MiR-486-5p enhances
cisplatin sensitivity of human muscle-invasive bladder cancer cells
by induction of apoptosis and down-regulation of metastatic genes.
Urol Oncol. 38:738.e9–738.e21. 2020. View Article : Google Scholar
|
|
39
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
40
|
Sturchio E, Berardinelli MG, Boccia P,
Zanellato M and Gioiosa S: MicroRNAs diagnostic and prognostic
value as predictive markers for malignant mesothelioma. Arch
Environ Occup Health. 75:471–482. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Reid G, Kao SC, Pavlakis N, Brahmbhatt H,
MacDiarmid J, Clarke S, Boyer M and van Zandwijk N: Clinical
development of TargomiRs, a miRNA mimic-based treatment for
patients with recurrent thoracic cancer. Epigenomics. 8:1079–1085.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Reid G, Johnson TG and van Zandwijk N:
Manipulating microRNAs for the treatment of malignant pleural
mesothelioma: Past, present and future. Front Oncol. 10:1052020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Seo HA, Moeng S, Sim S, Kuh HJ, Choi SY
and Park JK: MicroRNA-Based Combinatorial cancer therapy: Effects
of MicroRNAs on the efficacy of anti-cancer therapies. Cells.
9:292019. View Article : Google Scholar
|
|
44
|
Fu H, Tie Y, Xu C, Zhang Z, Zhu J, Shi Y,
Jiang H, Sun Z and Zheng X: Identification of human fetal liver
miRNAs by a novel method. FEBS Lett. 579:3849–3854. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Small EM, O'Rourke JR, Moresi V,
Sutherland LB, McAnally J, Gerard RD, Richardson JA and Olson EN:
Regulation of PI3-kinase/Akt signaling by muscle-enriched
microRNA-486. Proc Natl Acad Sci USA. 107:4218–4223. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Mees ST, Mardin WA, Sielker S, Willscher
E, Senninger N, Schleicher C, Colombo-Benkmann M and Haier J:
Involvement of CD40 targeting miR-224 and miR-486 on the
progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol.
16:2339–2350. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
He M, Wang G, Jiang L, Qiu C, Li B, Wang J
and Fu Y: MiR-486 suppresses the development of osteosarcoma by
regulating PKC-δ pathway. Int J Oncol. 50:1590–1600. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shao Y, Shen YQ, Li YL, Liang C, Zhang BJ,
Lu SD, He YY, Wang P, Sun QL, Jin YX and Ma ZL: Direct repression
of the oncogene CDK4 by the tumor suppressor miR-486-5p in
non-small cell lung cancer. Oncotarget. 7:34011–34021. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lang B and Zhao S: MiR-486 functions as a
tumor suppressor in esophageal cancer by targeting CDK4/BCAS2.
Oncol Rep. 39:71–80. 2018.
|
|
50
|
Amatya VJ, Mawas AS, Kushitani K, Mohi
El-Din MM and Takeshima Y: Differential microRNA expression
profiling of mesothelioma and expression analysis of miR-1 and
miR-214 in mesothelioma. Int J Oncol. 48:1599–1607. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu Y, Zhang J, Xing C, Wei S, Guo N and
Wang Y: MiR-486 inhibited osteosarcoma cells invasion and
epithelial-mesenchymal transition by targeting PIM1. Cancer
Biomark. 23:269–277. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang X, Song M, Kundu JK, Lee MH and Liu
ZZ: PIM Kinase as an executional target in cancer. J Cancer Prev.
23:109–116. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhao W, Qiu R, Li P and Yang J: PIM1: A
promising target in patients with triple-negative breast cancer.
Med Oncol. 34:1422017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chen J and Tang G: PIM-1 kinase: A
potential biomarker of triple-negative breast cancer. Onco Targets
Ther. 12:6267–6273. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yang H, He K, Dong W, Fang J, Zhong S,
Tang L and Long L: PIM-1 may function as an oncogene in cervical
cancer via activating the EGFR signaling. Int J Biol Markers.
35:67–73. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xu J, Xiong G, Cao Z, Huang H, Wang T, You
L, Zhou L, Zheng L, Hu Y, Zhang T and Zhao Y: PIM-1 contributes to
the malignancy of pancreatic cancer and displays diagnostic and
prognostic value. J Exp Clin Cancer Res. 35:1332016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Asati V, Mahapatra DK and Bharti SK: PIM
kinase inhibitors: Structural and pharmacological perspectives. Eur
J Med Chem. 172:95–108. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Abdul Rahim SN, Ho GY and Coward JI: The
role of interleukin-6 in malignant mesothelioma. Transl Lung Cancer
Res. 4:55–66. 2015.PubMed/NCBI
|
|
59
|
Donnenberg AD, Luketic JD and Donnenberg
VS: Secretome of pleural effusions associated with non-small cell
lung cancer (NSCLC) and malignant mesothelioma: Therapeutic
implications. Oncotarget. 10:6456–6465. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Nakano T, Chahinian AP, Shinjo M, Tonomura
A, Miyake M, Togawa N, Ninomiya K and Higashino K: Interleukin 6
and its relationship to clinical parameters in patients with
malignant pleural mesothelioma. Br J Cancer. 77:907–912. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Acencio MM, Soares B, Marchi E, Silva CS,
Teixeira LR and Broaddus VC: Inflammatory cytokines contribute to
asbestos-induced injury of mesothelial cells. Lung. 193:831–837.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Topley N, Jörres A, Luttmann W, Petersen
MM, Lang MJ, Thierauch KH, Müller C, Coles GA, Davies M and
Williams JD: Human peritoneal mesothelial cells synthesize
interleukin-6: Induction by IL-1 beta and TNF alpha. Kidney Int.
43:226–233. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Adachi Y, Aoki C, Yoshio-Hoshino N,
Takayama K, Curiel DT and Nishimoto N: Interleukin-6 induces both
cell growth and VEGF production in malignant mesotheliomas. Int J
Cancer. 119:1303–1311. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Norbet C, Joseph A, Rossi SS, Bhalla S and
Gutierrez FR: Asbestos-related lung disease: A pictorial review.
Curr Probl Diagn Radiol. 44:371–382. 2015. View Article : Google Scholar
|
|
65
|
Hiddinga BI, Rolfo C and van Meerbeeck JP:
Mesothelioma treatment: Are we on target? A review. J Adv Res.
6:319–330. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Nicolini F, Bocchini M, Bronte G, Delmonte
A, Guidoboni M, CrinO L and Mazz M: Malignant pleural mesothelioma:
State-of-the-Art on current therapies and promises for the future.
Front Oncol. 9:15192020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sacco JJ, Kenyani J, Butt Z, Carter R,
Chew HY, Cheeseman LP, Darling S, Denny M, Urbe S, Clague MJ and
Coulson JM: Loss of the deubiquitylase BAP1 alters class I histone
deacetylase expression and sensitivity of mesothelioma cells to
HDAC inhibitors. Oncotarget. 6:13757–13771. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Guazzelli A, Meysami P, Bakker E,
Demonacos C, Giordano A, Krstic-Demonacos M and Mutti L: BAP1
status determines the sensitivity of malignant mesothelioma cells
to gemcitabine treatment. Int J Mol Sci. 20:4292019. View Article : Google Scholar :
|
